

## GeNeuro and the Karolinska Institutet's Academic Specialist Center (ASC) to Present ProTECT-MS Study of Temelimab at MSVirtual2020

- Poster presentation describes rationale of administering temelimab after treatment with rituximab in relapsing multiple sclerosis (MS) patients to address disease progression independent of relapse activity (PIRA)
- Results of ProTECT-MS study expected in 2021

**Geneva, Switzerland, September 8, 2020, 7:30am CEST** – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the company and the Karolinska Institutet's Academic Specialist Center (ASC) will present the rationale of its new Phase 2 study at MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting), held September 11-13, 2020. The trial, which is evaluating the administration of temelimab in patients with relapsing MS to address disease progression independent of relapses following treatment with rituximab, is being conducted at the Karolinska Institutet's Academic Specialist Center, Stockholm, Sweden.

The one-year ProTECT-MS study will enrol 40 patients whose disability progresses in absence of relapses. Although highly effective disease-modifying therapies are available today to suppress relapses and lesion formation, they have limited effect on MS disease progression and patient disability over time. The unmet medical need in MS are drugs that act against the pathogenesis of inflammation-independent neurodegeneration. Long-term data from the Phase 2 ANGEL-MS trial conducted by GeNeuro has shown that temelimab, a monoclonal antibody designed to neutralize a pathogenic retroviral envelope protein, pHERV-W Env expressed by microglial cells in MS lesion tissue\*, has a remarkably consistent neuroprotective effect on key MRI measures linked to MS disease progression.

By targeting fundamental underlying mechanisms of neurodegeneration in MS, such as neutralizing microglial-mediated damage, as well as restoring the remyelination capacity of oligodendrocyte precursor cells (OPCs), temelimab may address the critical unmet medical need of blocking disability progression independent of relapse activity in MS. Since temelimab has no significant anti-inflammatory effect, a cohort of patients previously treated with a highly effective disease modifying drug, such as the anti-CD20 antibody rituximab, but whose disability is increasing without relapses, will allow to properly explore temelimab's tissue protective and anti-neurodegenerative effects.

Abstracts are available on the MSVirtual2020 Website. E-posters will be made available on Friday, September 11 at 8:00 a.m. ET.

Details of the MSVirtual2020 e-Poster Presentation:

Abstract:	1803
Poster:	P0239
Title:	Temelimab for prevention of neurodegeneration: preclinical safety profile and design of the ProTECT-MS (temelimab following rituximab in RMS) study
Presentation Time:	September 11 at 9:30 am ET

\*Kremer et al., PNAS 2019

## About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 17 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)

## Contacts :

<b>GeNeuro</b>	<b>NewCap (France)</b>	<b>Halsin Partners</b>	<b>LifeSci Advisors</b>
Jesús Martin-Garcia	Louis-Victor Delouvrier / Mathilde Bohin (investors)	Mike Sinclair (media)	Chris Maggos (investors)
Chairman and CEO +41 22 552 4800 <a href="mailto:investors@geneuro.com">investors@geneuro.com</a>	+33 1 44 71 98 52 Nicolas Merigeau (media) +33 1 44 71 94 98 <a href="mailto:geneuro@newcap.eu">geneuro@newcap.eu</a>	+44 20 7318 2955 <a href="mailto:msinclair@halsin.com">msinclair@halsin.com</a>	+41 79 367 6254 <a href="mailto:chris@lifesciadvisors.com">chris@lifesciadvisors.com</a>

## Disclaimer:

This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "plan," "potential," "predict," "objective," "should," or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.